Literature DB >> 9500720

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.

P Mathurin1, J Moussalli, J F Cadranel, V Thibault, F Charlotte, P Dumouchel, A Cazier, J M Huraux, B Devergie, M Vidaud, P Opolon, T Poynard.   

Abstract

In hepatitis C virus (HCV) patients with persistently normal alanine transaminase (ALT), the progression rate of fibrosis is unknown. The aims of this study were: 1) to compare HCV patients with normal ALT (group I) with HCV patients with elevated ALT (group II) matched on independent factors associated with fibrosis; and 2) to assess the progression rate of fibrosis. One hundred two HCV patients were included in each group. Histological lesions were staged using the METAVIR score. We defined fibrosis progression per year as the ratio of the fibrosis stage in METAVIR units to the duration of infection. In group I, ALT values were normal, and lower than in group II (25 vs. 127 IU/L; P < .0001). HCV RNA was present less frequently in group I (66% vs. 97%; P < .0001). There were no significant differences for viremia and genotypes. Histological activities were lower in group I (0.6 vs. 1.38; P < .0001). The stage of fibrosis was lower in group I (0.95 vs. 1.8; P < .001). The median progression rate of fibrosis was lower in group I (0.05 vs. 0.13; P < .001). In group I, after exclusion of negative HCV-RNA patients, the median progression rate of positives remained lower (0.05 vs. 0.13; P < .001). In group I, all cirrhotic patients (n = 3) were heavy drinkers. HCV patients with normal ALT showed weaker histological activity and lower fibrosis scores, and the progression rate of fibrosis was twice as slow as in HCV patients with elevated ALT. In these patients, severe fibrosis was associated with high alcohol consumption.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500720     DOI: 10.1002/hep.510270333

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

Review 2.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels.

Authors:  Filiz Akyüz; Nuray Polat; Sabahattin Kaymakoglu; Nevzat Aksoy; Kadir Demir; Fatih Beşişik; Selim Badur; Yilmaz Cakaloglu; Atilla Okten
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 4.  Ursodeoxycholic acid in chronic hepatitis C.

Authors:  Raoul Poupon; Lawrence Serfaty
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

5.  Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.

Authors:  M G Rumi; F De Filippi; C La Vecchia; M F Donato; S Gallus; E Del Ninno; M Colombo
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 6.  Kidney transplantation from donors with hepatitis C infection.

Authors:  Massimiliano Veroux; Daniela Corona; Nunziata Sinagra; Alessia Giaquinta; Domenico Zerbo; Burcin Ekser; Giuseppe Giuffrida; Pietro Caglià; Riccardo Gula; Vincenzo Ardita; Pierfrancesco Veroux
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

7.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

9.  Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.

Authors:  Jiajia Dong; Olajide E Olaleye; Rongrong Jiang; Jing Li; Chuang Lu; Feifei Du; Fang Xu; Junling Yang; Fengqing Wang; Weiwei Jia; Chuan Li
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

10.  The management of chronic viral hepatitis: A Canadian consensus conference 2004.

Authors:  Morris Sherman; Vincent Bain; Jean-Pierre Villeneuve; Robert P Myers; Curtis Cooper; Steven Martin; Catherine Lowe
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.